Alexion Pharm Inc(NASDAQ:ALXN) stock News

ALXN Latest News, Press Relases and Analysis

All

Press Releases

9 days ago - By: Resolution Therapeutics - Mentions: IMCR

Resolution Therapeutics appoints Lucy Singah as Chief Financial Officer and Daniel Kennedy as Chief Business Officer

2 years ago - By: Bloomberg - Mentions: PTLA

Ex-Pharma Executive Avoids Prison for Tipping Pal About Merger

4 years ago - By: The Motley Fool - Mentions: MRNA AZN

Will Moderna’s Tenure on the S&P 500 Index Be Short-Lived?

4 years ago - By: Zacks Investment Research

Alexion Pharmaceuticals (ALXN) Earnings Expected to Grow: Should You Buy?

4 years ago - By: Barron's - Mentions: MRNA SPX LB AZN

Moderna Stock Leapt 4.5% After Joining S&P 500. Why Analysts Don't Expect More Gains.

4 years ago - By: Zacks Investment Research - Mentions: TECH

ALXN vs. TECH: Which Stock Is the Better Value Option?

4 years ago - By: Zacks Investment Research - Mentions: JNJ ABBV

AbbVie (ABBV) Venclexta Gets Breakthrough Therapy Tag for MDS

4 years ago - By: Benzinga - Mentions: AZN

Alexion's Ultomiris Sales Almost Doubles In 1H 2021 As $39B AstraZeneca Deal Looms

4 years ago - By: Zacks Investment Research - Mentions: RGEN

Bayer's (BAYRY) Parkinson's Disease Therapy Gets Fast Track Tag

4 years ago - By: Yahoo Finance - Mentions: VZ TSLA MRNA

Moderna stock 'has taken on a life of its own' ahead of S&P 500 entrance

4 years ago - By: Zacks Investment Research

Moderna Soars on Inclusion to S&P 500: ETFs in Focus

4 years ago - By: The Motley Fool - Mentions: AZN

AstraZeneca's Acquisition of Alexion Is Nearly a Done Deal, But Is It a Good Deal?

4 years ago - By: Benzinga - Mentions: SPX MRNA

Moderna Options Traders Mixed On S&P 500 Inclusion

4 years ago - By: Investor's Business Daily - Mentions: AZN MRNA AMGN PFE ...

Moderna Stock — Soon To Join S&P 500 — Rockets To Yet Another Record

4 years ago - By: InvestorPlace - Mentions: MRNA AZN

MRNA Stock: 10 Things to Know About Moderna as It Gets Ready to Join the S&P 500

4 years ago - By: Barron's - Mentions: DJIA SPX COMP NIK ...

Stocks Are Higher After Retail Sales Top Expectations

4 years ago - By: Barron's - Mentions: NIK 8301 UKX DJIA ...

Global Stocks Mixed Ahead of U.S. Retail Sales Data

4 years ago - By: Alexion Pharmaceuticals, Inc.

Alexion Announces Positive Topline Results from Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Adults with Generalized Myasthenia Gravis (gMG)

4 years ago - By: Zacks Investment Research - Mentions: GILD ADPT GLPG

Galapagos (GLPG) Falls on Inflammatory Study Data Readout

4 years ago - By: Zacks Investment Research

Why Alexion Pharmaceuticals (ALXN) is a Top Momentum Stock for the Long-Term

4 years ago - By: Zacks Investment Research

Here is Why Growth Investors Should Buy Alexion (ALXN) Now

4 years ago - By: Barron's - Mentions: AZN JNJ PFE MRK ...

Vaccine Maker AstraZeneca’s Strong Drug Pipeline Could Lift the Stock Higher for Years

4 years ago - By: Zacks Investment Research - Mentions: AZN ZTS

AstraZeneca (AZN) Gets EC's Clearance for Alexion Acquisition

4 years ago - By: Zacks Investment Research - Mentions: GMAB

ALXN or GMAB: Which Is the Better Value Stock Right Now?

4 years ago - By: Investor's Business Daily - Mentions: TBIO MRVI

Alexion Pharm Inc (ALXN) Stock News

ALXN Latest News, Press Relases and Analysis

Resolution Therapeutics appoints Lucy Singah as Chief Financial Officer and Daniel Kennedy as Chief Business Officer

Ex-Pharma Executive Avoids Prison for Tipping Pal About Merger

Will Moderna’s Tenure on the S&P 500 Index Be Short-Lived?

Alexion Pharmaceuticals (ALXN) Earnings Expected to Grow: Should You Buy?

Moderna Stock Leapt 4.5% After Joining S&P 500. Why Analysts Don't Expect More Gains.

ALXN vs. TECH: Which Stock Is the Better Value Option?

AbbVie (ABBV) Venclexta Gets Breakthrough Therapy Tag for MDS

Alexion's Ultomiris Sales Almost Doubles In 1H 2021 As $39B AstraZeneca Deal Looms

Bayer's (BAYRY) Parkinson's Disease Therapy Gets Fast Track Tag

Moderna stock 'has taken on a life of its own' ahead of S&P 500 entrance

Moderna Soars on Inclusion to S&P 500: ETFs in Focus

AstraZeneca's Acquisition of Alexion Is Nearly a Done Deal, But Is It a Good Deal?

Moderna Options Traders Mixed On S&P 500 Inclusion

Moderna Stock — Soon To Join S&P 500 — Rockets To Yet Another Record

MRNA Stock: 10 Things to Know About Moderna as It Gets Ready to Join the S&P 500

Stocks Are Higher After Retail Sales Top Expectations

Global Stocks Mixed Ahead of U.S. Retail Sales Data

Alexion Announces Positive Topline Results from Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Adults with Generalized Myasthenia Gravis (gMG)

Galapagos (GLPG) Falls on Inflammatory Study Data Readout

Why Alexion Pharmaceuticals (ALXN) is a Top Momentum Stock for the Long-Term

Here is Why Growth Investors Should Buy Alexion (ALXN) Now

Vaccine Maker AstraZeneca’s Strong Drug Pipeline Could Lift the Stock Higher for Years

AstraZeneca (AZN) Gets EC's Clearance for Alexion Acquisition

ALXN or GMAB: Which Is the Better Value Stock Right Now?

Translate Bio Stock Sees Relative Strength Rating Jump To 88